The full Eli Lilly (LLY) reaction history

LLY news moved a median of +0.08% by the close. Every LLY news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the LLY overview →

Half of the 393 LLY news events with a measured close landed between -0.79% and +1.02%; 53% closed up.

By year and event type

LLY reaction counts across 4 years.

Event type2026202520242023Total
Press release1141169315338
SEC filing · Form 8-K6913028
SEC filing · Form 10-Q33309
SEC filing · Form 10-K11103
SEC filing · Form 11-K11103
SEC filing · Form DEF11103
SEC filing · Form DEFA14A11103
SEC filing · Form PRE11103
SEC filing · Form SD11103
SEC filing · Form S-3ASR01001
All types12913511515394

Counts from the full measured window for LLY, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older LLY news pages.

Page 1 is the LLY overview; pages 2–8 carry the rest of the measured list.

The 10 most recent LLY reactions.

DateHeadlineEventSource5-minTo close
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesityPress releasePR Newswire-0.26%+0.92%
Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waitingPress releasePR Newswire+0.67%+2.15%
Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight lossPress releasePR Newswire-0.23%+2.54%
Lilly and Hims & Hers expand access to FDA-approved Lilly medicinesPress releasePR Newswire+1.02%+0.64%
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesityPress releasePR Newswire-0.12%-4.81%
Form 10-Q ELI LILLY & Co For: Sep 30SEC filing · Form 10-QSEC EDGAR-0.17%+0.57%
Form 8-K ELI LILLY & Co For: Oct 29SEC filing · Form 8-KSEC EDGAR+3.07%+2.35%
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolioPress releasePR Newswire+3.07%+2.35%
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialPress releasePR Newswire+0.79%+1.76%
Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global MarketsPress releasePR Newswire+0.79%+1.76%

384 more LLY reactions are behind a free account. Create one to see all 394 measured LLY events — the same point-in-time reactions, every headline.

See all 394 LLY events →

No credit card · 100 free credits/mo

Keep exploring

More LLY: earnings → · analyst actions → · SEC filings → · LLY overview →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Johnson & Johnson (JNJ)2,000++0.06%56%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.